Ovarian response to human menopausal gonadotropin following suppression with oral contraceptives.
The main conclusion of this study is that a profound suppression of the pituitary and ovary can be associated with an inadequate response which may require a longer or different regimen of stimulation to achieve the desired outcome for IVF. We suggest that a pretreatment determination of E2 and gonadotropins can be of value to predict the nature of ovarian response in women with suppressed pituitary-ovarian function.
D003276:Contraceptives, Oral / Q000494:pharmacology / Q000627:therapeutic use*; D003277:Contraceptives, Oral, Combined / Q000494:pharmacology / Q000627:therapeutic use; D004338:Drug Combinations; D004958:Estradiol / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008596:Menotropins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008656:Mestranol / Q000494:pharmacology / Q000627:therapeutic use; D009640:Norethindrone / Q000494:pharmacology / Q000627:therapeutic use; D006080:Ovarian Follicle / Q000033:anatomy & histology; D010053:Ovary / Q000187:drug effects / Q000502:physiology*; D010902:Pituitary Gland / Q000187:drug effects / Q000502:physiology; D011374:Progesterone / Q000097:blood
D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D004338:Drug Combinations; D011374:Progesterone; D004958:Estradiol; D008596:Menotropins; C014715:Norinyl; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D008656:Mestranol; D009640:Norethindrone